Generic

Linagliptin.

Indications

Linagliptin is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults.

• As monotherapy: in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance or contraindicated due to renal impairment.
• As combination therapy: in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Pharmacology

Linagliptin is shown to move forward glycemic control in patients with sort 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), a protein that debases the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose subordinate insulinotropic polypeptide). Hence, Linagliptin increments the concentrations of dynamic incretin hormones, invigorating the discharge of affront from pancreatic beta (β) cells in a glucose-dependent way and diminishing the emission of glucagon from pancreatic alpha (α) cells within the circulation.

Dosage & Administration

Linagliptin 5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulfonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.

Patients with renal impairment: No dose adjustment required. Linagliptin can be taken with or without a meal at any time of the day.

Interaction

Linagliptin could be a frail competitive and powerless to direct mechanism-based inhibitor of CYP isozyme CYP3A4 but does not hinder other CYP isozymes. The chance for clinically significant intuition by other restorative items on linagliptin is moo and in clinical considers linagliptin had no clinically significant impact on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin, or verbal contraceptives.

Contraindications

Hypersensitivity to the active substance or any excipient.

Side Effect

When metformin and sulfonylurea are used together, hypoglycemia, nasopharyngitis, cough, and pancreatitis might occur.

Pregnancy & Lactation

Pregnancy category B. There are no satisfactory and well-controlled ponders in pregnant ladies. So, Linagliptin tablets ought to be utilized amid pregnancy as it were in the case clearly required. It isn’t known whether Linagliptin passes into breast drain or not.

Precautions & Warnings

Hypersensitivity to the active ingredient or any excipient.

Therapeutic Class

Dipeptidyl Peptidase-4 (DPP-4) inhibitor.

Storage Conditions

Store in a cool and dry place, protected from light.

Pharmaceutical Name

Healthcare Pharmaceuticals Ltd.